April 22, 2024

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing
About this webinar

Toxicity testing is on the cusp of transitioning away from expensive and ethically challenged animal-based methods, towards more efficient alternative approaches. Concurrently, advances in technologies that examine sub-lethal effects on gene expression have led to increased interest in the concept of transcriptomic points of departure (tPODs), or the threshold concentration beyond which a concerted response in gene expression may be expected, indicating the potential for adverse effects at the organismal level.

These concentrations have been found to be lower than (i.e. protective of) benchmark effect concentrations that can cause mortality and reproductive defects. Consequentially, there is growing scientific and regulatory interest in tPODs for applications in chemical screening and prioritization.

Hear from researchers from McGill University, as they present case studies in optimizing and advancing efficient workflows that couple in vitro exposures with ultraplexed library preparation using the QIAseq UPXome RNA Library Kit. This approach has increased the throughput of differential expression and dose-response analysis for tPODs derivation.

Additionally, learn how combining ultraplexed library preparation with mosquito® automated liquid handling has improved efficiency in two ways:

  • Shortening the overall library preparation protocol time
  • Reducing reagent usage by a half by miniaturizing protocol volumes
register now

Our latest News

discover more
Green hydrogen for a climate-neutral industry: InnovationLab organizes Clean Tech Innovation Day

Green hydrogen for a climate-neutral industry: InnovationLab organizes Clean Tech Innovation Day

Heidelberg, Germany, November 6, 2024 – The technology transfer platform InnovationLab is looking forward to the premiere of a new event format: hydrogen experts from Germany and abroad are expected to attend the Clean Tech Innovation Day on Monday, November 11 (9 a.m. to 6 p.m.). Together with its two co-partners, the Rhine-Neckar metropolitan region […]

New findings on cell types and their interactions in multiple sclerosis

New findings on cell types and their interactions in multiple sclerosis

An international research team led by Professor Dr. Lucas Schirmer and Professor Dr. Julio Saez-Rodriguez from the Medical Faculties of Heidelberg University, in Mannheim and Heidelberg, has studied the different cell types in so-called subcortical lesions, tissue damage to deep brain structures, at different stages of multiple sclerosis (MS) and investigated how they communicate. In […]

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Partnership to Combine AbbVie’s Oncology Expertise with EvolveImmune’s Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies, today announced a collaboration […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp